ea0090ep593 | Endocrine-related Cancer | ECE2023
Angelousi Anna
, Karampela Athina
, Kazanas Spyridon
, Papalexis Petros
, Lafioniatis Alexandros
, Siampanopoulou Vasiliki
, Mytareli Chrysoula
, Theochari Maria
, Stephanou Dimitra
, Ziogas Dimitrios
, Gogas Helen
Background: Immune checkpoint inhibitors (ICIs) (anti-CTLA-4, PD-1 inhibitors, PD-L1 inhibitors) are considered a widely used therapeutic choice for several cancer types. However ICI therapy is frequently complicated by adverse events; endocrine toxicities are the most common ones.Methods: To assess in a retrospective observational study in a tertiary hospital the incidence and the characteristics of the immunotherapy-related endocrine adverse events (ir...